Thomas Meek is currently the Senior Director of Cardiometabolic Disorders at Amgen, where they lead innovative research in identifying and validating therapeutic targets for metabolic diseases. They have a rich background in pharmacological research, focusing on anti-obesity and anti-diabetic therapies, complemented by their past roles at Novo Nordisk and the University of Washington. Thomas earned a PhD in Evolutionary Physiology from the University of California, Riverside, after completing a BS in Animal Physiology at the University of Delaware. Their research expertise includes advanced screening technologies and the physiological mechanisms of energy regulation.
This person is not in the org chart
This person is not in any teams
This person is not in any offices